Lathrop GPM Partner Michael Spellberg, Ph.D. recently authored an article in Biotechnology Law Report titled “Oligonucleotide Therapeutics Patenting: Strategies for Success,” offering key insights into the evolving landscape of intellectual property protection for these complex molecules.
The piece explores how recent advances in oligonucleotide chemistry and therapeutic applications are reshaping patent strategy, emphasizing the importance of claim clarity, structural specificity, and regulatory alignment. It also highlights how early engagement with patent counsel can help innovators navigate challenges in securing robust protection for novel oligonucleotide-based therapies.
Read the full article here [SUBSCRIPTION REQUIRED]: Oligonucleotide Therapeutics Patenting: Strategies for Success